Anna Krichevsky is an Associate Professor of Neurology/Neurobiology at Harvard Medical School and the Center for Neurologic Diseases, Neurology, Brigham and Women’s Hospital. She received her MSc. and Ph.D. degrees from the Hebrew University of Jerusalem, Israel, and completed postdoctoral training at Harvard Medical School in Boston. As a postdoctoral fellow, she isolated neuronal RNA granules and pioneered the work that led to the recognition of microRNA (miRNA) functions and RNA interference mechanisms in brain physiology and pathology. She performed the first successful RNA interference in mammalian neurons, contributed to the identification of miRNAs in the mammalian brain, developed the first high-throughput arrays for miRNA expression profiling, and discovered one of the first oncogenic miRNA, miR-21, which is currently a promising target for various human diseases. Her laboratory identified and studied key miRNAs involved in brain tumors and neurodegenerative disorders such as Alzheimer’s disease. Her laboratory also pioneered the identification of miRNA biomarkers for diagnostics and monitoring of primary and metastatic brain tumors. Her innovative research, featured in HMS Focus, NIH, Reuters Science News, Health Canal, and The Boston Globe, is geared towards RNA medicine and based on multiple collaborations. She also serves on the Executive Committee of the HMS Initiative for RNA Medicine, established to translate RNA research into clinical practice.
Anna Krichevsky is an Associate Professor of Neurology/Neurobiology at Harvard Medical School and the Center for Neurologic Diseases, Neurology, Brigham and Women’s Hospital. She received her MSc. and Ph.D. degrees from the Hebrew University of Jerusalem, Israel, and completed postdoctoral training at Harvard Medical School in Boston. As a postdoctoral fellow, she isolated neuronal RNA granules and pioneered the work that led to the recognition of microRNA (miRNA) functions and RNA interference mechanisms in brain physiology and pathology. She performed the first successful RNA interference in mammalian neurons, contributed to the identification of miRNAs in the mammalian brain, developed the first high-throughput arrays for miRNA expression profiling, and discovered one of the first oncogenic miRNA, miR-21, which is currently a promising target for various human diseases. Her laboratory identified and studied key miRNAs involved in brain tumors and neurodegenerative disorders such as Alzheimer’s disease. Her laboratory also pioneered the identification of miRNA biomarkers for diagnostics and monitoring of primary and metastatic brain tumors. Her innovative research, featured in HMS Focus, NIH, Reuters Science News, Health Canal, and The Boston Globe, is geared towards RNA medicine and based on multiple collaborations. She also serves on the Executive Committee of the HMS Initiative for RNA Medicine, established to translate RNA research into clinical practice.